Overview
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist that has been one of the most widely researched peptide compounds of the past decade. Its selective GLP-1 receptor binding profile makes it a valuable research tool for studying incretin pharmacology, particularly for comparative studies against dual-agonist compounds such as Tirzepatide.
Nova Biolabs supplies Semaglutide 20mg in lyophilised form from UK domestic stock.
Key Research Areas
GLP-1 Receptor Pharmacology
As a selective GLP-1 agonist, Semaglutide is a foundational tool for studying GLP-1 receptor binding kinetics, activation and downstream signalling without GIP or glucagon receptor involvement.
Comparative Incretin Studies
Widely used as the single-agonist reference compound in studies comparing GLP-1 only vs. dual (Tirzepatide) vs. triple (Retatrutide) receptor activation outcomes.
Pancreatic Beta Cell Research
Studied in beta cell models for its effects on insulin secretion signalling pathways, particularly glucose-dependent insulinotropic mechanisms.
Neuropeptide Signalling Research
GLP-1 receptors are expressed in the central nervous system — Semaglutide is used in neuronal cell models to study appetite and reward signalling pathways.
Product Specifications
| Format | Lyophilised powder |
| Quantity | 20mg per vial |
| Grade | Research Grade |
| Storage | Refrigerate at 2–8°C. Stable 24 months lyophilised. |
| Origin | UK domestic stock |
| Research use | In vitro / laboratory use only |
Frequently Asked Questions
Commonly Stacked With
Compounds researchers often study alongside this one, and why.
The reference single-agonist compound in comparative studies against dual/triple agonists — often ordered together for head-to-head receptor research.
Amylin and GLP-1 receptor pathways are frequently studied together — Cagrilintide is often paired with a GLP-1 agonist for combined appetite-signalling research.
Tissue-repair peptides are commonly studied alongside GLP-1 research given the shared interest in metabolic and recovery signalling during extended protocols.